DUAL-PATHWAY BLOCKADE THERAPY OFFERS HOPE FOR RARE, HARD-TO-TREAT GYNAECOLOGICAL CLEAR CELL CANCERS

International study demonstrates promising clinical activity of pembrolizumab plus lenvatinib in recurrent disease, addressing a longstanding treatment gap SINGAPORE, April 23, 2026 /PRNewswire/ -- Before her cancer diagnosis in early 2017, 48-year-old Caitlin Delaney, who is based in...